Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Stomach Neoplasms 9 Colorectal Neoplasms 4 Head and Neck Neoplasms 3 Colonic Neoplasms 3 Squamous Cell Carcinoma of Head and Neck 2 Gallbladder Neoplasms 2 Esophageal Neoplasms 2 Carcinoma, Non-Small-Cell Lung 2 Carcinoma, Hepatocellular 2 Uterine Cervical Neoplasms 1 Stage IA Pancreatic Adenocarcinoma 1 Recurrence 1 Rectal Neoplasms 1 Pancreatic Neoplasms 1 Mouth Neoplasms 1 Lung Neoplasms 1 HER2-positive Gastric Cancer 1 Fruquintinib 1 For Patients With Colorectal Cancer Liver Metastases Who Were Not Able to Curative Surgical Resection.Focused on the Treatment Effect With the Quintuple Method 1 Extrapancreatic Neuroendocrine Tumor 1 Cholangiocarcinoma 1 Biliary Tract Neoplasms 1 Adenoma, Islet Cell 1

Interventions

raltitrexed 1 potassium oxonate 1 gimeracil 1 Tegafur 1 S 1 (combination) 1 Irinotecan 1 HMPL-013 1 Capecitabine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Unknown × Fruquintinib × Tegafur × Clear all

NCT06427005 2025-01-22

Fruquintinib Plus S-1 and Raltitrexed (RSF) for MCRC

West China Hospital

Phase 2 Unknown

Fruquintinib

Data powered by HemOnc (CC BY 4.0) Colophon ⚡